MedTrace Logo

Change in Body Weight During Treatment of Advanced Colorectal Cancer

NCT04232748 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 264

Last updated 2020-01-18

No results posted yet for this study

Summary

Colorectal cancer (CRC) is a significant and growing health burden in Hong Kong. According to data from Hong Kong Cancer Registry, CRC ranked the first in incidence and the second in mortality, with around 5,000 new cases diagnosed and more than 2,000 cancer-related mortality in 2014. The investigators aim to evaluate the association between serial weight change during first line treatment and outcomes in patients with metastatic CRC.

Conditions

  • Cancer, Colorectal
  • Chemotherapy Effect
  • Weight Loss
  • Prognosis

Interventions

DRUG

first line systemic treatment for colorectal cancer

systemic chemotherapy (capecitabine or fluorouracil, oxaliplatin or irinotecan, with or without biological agents including cetuximab, bevacizumab, or panitumumab.

Sponsors & Collaborators

  • Tuen Mun Hospital

    lead OTHER_GOV

Principal Investigators

  • Shing Fung Lee, MBBS, M Sc · Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2022-03-01
Completion
2022-03-01

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04232748 on ClinicalTrials.gov